Smartlab Europe

Bharat Serums and Vaccines invests Rs 200 Cr in new biopharmaceutical manufacturing plant in Genome Valley

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Online Medicine in India Where Ganaton Total Fits in Modern Digestive Care

The demand for online medicine delivery in India has...

Roche AI Factory Expansion to Boost Pharma R&D Capacity

Swiss drugmaker Roche has expanded its artificial intelligence infrastructure...

How Smart Labs Are Reshaping Pharmaceutical Research Infrastructure

Pharmaceutical research and development environments are in a state...
- Advertisement -

Bharat Serums and Vaccines Limited (BSV) hosted the groundbreaking ceremony of its new manufacturing plant at Genome Valley in Hyderabad, Telangana, in the presence of K.T Rama Rao, Minister for Municipal Administration and Urban Development; Industries and Commerce; and Information Technology, Electronics and Communications of Telangana.

BSV currently has a manufacturing facility in Ambernath, Maharashtra that caters to domestic and more than 80 export markets and a manufacturing facility in Aachen, Germany, that serves the international markets.

The new manufacturing facility in Genome Valley will cover an area of 10 acres and involve an investment of Rs 200 crore. It aims to provide long-term employment opportunities to the people of the Telangana State as well as upskilling of capabilities.

With this manufacturing facility, BSV aims to significantly increase its capacity in producing injectables with the commissioning of the fill-finish formulation line in phase 1 and an additional multi-product line in phase 2 of the project. The manufacturing facility endeavors to produce world-class products that adhere to International Quality Systems while complying to the Indian regulatory norms of Schedule M as well as the Global regulatory requirements in the world. The facility will produce women health products, rabies vaccines, immunoglobulins, hormones, among others.

Latest stories

Related stories

Online Medicine in India Where Ganaton Total Fits in Modern Digestive Care

The demand for online medicine delivery in India has...

Roche AI Factory Expansion to Boost Pharma R&D Capacity

Swiss drugmaker Roche has expanded its artificial intelligence infrastructure...

How Smart Labs Are Reshaping Pharmaceutical Research Infrastructure

Pharmaceutical research and development environments are in a state...

Cosentyx Secures FDA Approval for Paediatric HS Treatment

Novartis has received approval from the US Food and...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »